IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 352 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $17,470,281 | -31.0% | 366,561 | -37.2% | 0.00% | -33.3% |
Q1 2024 | $25,323,220 | -15.8% | 584,158 | -1.7% | 0.01% | -25.0% |
Q4 2023 | $30,063,115 | +7.3% | 594,250 | -3.8% | 0.01% | 0.0% |
Q3 2023 | $28,029,264 | +11.5% | 617,930 | +0.8% | 0.01% | +14.3% |
Q2 2023 | $25,146,917 | +12.4% | 612,891 | -2.1% | 0.01% | +16.7% |
Q1 2023 | $22,378,608 | -2.6% | 626,150 | +3.0% | 0.01% | -14.3% |
Q4 2022 | $22,965,670 | -24.7% | 608,040 | -11.9% | 0.01% | -30.0% |
Q3 2022 | $30,513,000 | +13.8% | 689,872 | -4.7% | 0.01% | +25.0% |
Q2 2022 | $26,802,000 | -14.1% | 723,995 | -14.0% | 0.01% | 0.0% |
Q1 2022 | $31,198,000 | +26.4% | 842,284 | +3.9% | 0.01% | +33.3% |
Q4 2021 | $24,678,000 | -13.8% | 810,966 | -5.0% | 0.01% | 0.0% |
Q3 2021 | $28,622,000 | -14.7% | 853,370 | +1.4% | 0.01% | -14.3% |
Q2 2021 | $33,564,000 | -35.5% | 841,431 | -27.3% | 0.01% | -41.7% |
Q1 2021 | $52,018,000 | -20.0% | 1,156,999 | +0.5% | 0.01% | -25.0% |
Q4 2020 | $65,061,000 | +49.4% | 1,150,718 | +25.3% | 0.02% | +33.3% |
Q3 2020 | $43,561,000 | -23.6% | 918,027 | -5.1% | 0.01% | -29.4% |
Q2 2020 | $57,042,000 | +24.7% | 967,449 | +0.0% | 0.02% | +6.2% |
Q1 2020 | $45,733,000 | -26.3% | 967,293 | -5.9% | 0.02% | -5.9% |
Q4 2019 | $62,083,000 | -0.4% | 1,027,704 | -1.2% | 0.02% | -5.6% |
Q3 2019 | $62,342,000 | -9.9% | 1,040,580 | -3.3% | 0.02% | -10.0% |
Q2 2019 | $69,174,000 | -16.2% | 1,076,304 | +5.9% | 0.02% | -20.0% |
Q1 2019 | $82,521,000 | +34.1% | 1,016,637 | -10.7% | 0.02% | +25.0% |
Q4 2018 | $61,537,000 | +2.4% | 1,138,308 | -2.3% | 0.02% | +17.6% |
Q3 2018 | $60,104,000 | +19.3% | 1,165,267 | -3.6% | 0.02% | +13.3% |
Q2 2018 | $50,366,000 | +0.0% | 1,208,703 | +5.8% | 0.02% | 0.0% |
Q1 2018 | $50,346,000 | -9.3% | 1,142,168 | +3.5% | 0.02% | -6.2% |
Q4 2017 | $55,497,000 | -5.1% | 1,103,329 | -4.4% | 0.02% | -11.1% |
Q3 2017 | $58,510,000 | -1.6% | 1,154,048 | -1.3% | 0.02% | -5.3% |
Q2 2017 | $59,467,000 | +25.6% | 1,169,015 | -0.7% | 0.02% | +26.7% |
Q1 2017 | $47,344,000 | -17.4% | 1,177,720 | -1.7% | 0.02% | -25.0% |
Q4 2016 | $57,318,000 | +84.5% | 1,198,363 | +41.3% | 0.02% | +81.8% |
Q3 2016 | $31,067,000 | +53.2% | 847,912 | -2.6% | 0.01% | +37.5% |
Q2 2016 | $20,281,000 | -40.9% | 870,787 | +2.8% | 0.01% | -42.9% |
Q1 2016 | $34,310,000 | -5.5% | 847,168 | +39.8% | 0.01% | 0.0% |
Q4 2015 | $36,288,000 | – | 605,927 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |